Mutant BRAF V600E peptide epitope presented on MHC class II (BRAF V600E-MHC II)

The Mutant BRAF V600E peptide epitope presented on MHC class II is a tumor-specific neoantigen complex that serves as a critical target for cancer immunotherapy. The V600E mutation in the BRAF kinase is a common driver in various malignancies, including melanoma, colorectal cancer, and thyroid cancer, and it creates a unique amino acid sequence not present in normal tissues (1.4.1). When this mutant peptide is processed and presented by Major Histocompatibility Complex (MHC) class II molecules, it can be recognized by CD4+ T helper cells, which play a pivotal role in orchestrating the antitumor immune response (1.4.3, 1.4.5). Therapeutic strategies targeting this complex include peptide-based vaccines, such as ELI-007 and NeoAg-mBRAF, which aim to prime and expand mutation-specific T cells (1.3.1, 1.4.1). Additionally, BRAF and MEK inhibitors have been shown to enhance the presentation of this epitope by upregulating MHC class II expression on tumor cells, suggesting a synergistic potential between targeted therapy and immunotherapy (1.2.2, 1.4.3). However, tumors may develop resistance through the downregulation of MHC class II or the epigenetic silencing of its master regulator, CIITA (1.4.3).

Other names

BRAF V600E neoantigenBRAF V600E MHC-II complexBRAF V600E-derived CD4+ T cell epitopeneoAg-mBRAFBRAF V600E-derived MHC II-restricted neoantigen

Therapeutic vaccines deliver the mutant BRAF V600E peptide to antigen-presenting cells, which then present the epitope on MHC class II molecules to activate mutation-specific CD4+ T cells (1.4.1). These T cells provide essential help for CD8+ T cell responses and can exert direct antitumor effects through the secretion of cytokines like IFN-gamma (1.4.5). BRAF and MEK inhibitors further enhance this mechanism by increasing the expression of MHC class II molecules on the tumor cell surface, making the tumor more visible to the immune system (1.2.2, 1.4.3).